SRPIN340 inhibits serine-arginine-rich protein kinase 1 (SRPK1), exhibiting antiviral, anti-angiogenic, and anticancer chemotherapeutic activities. In vitro, SRPIN340 inhibits replication of hepatitis C virus (HCV). In animal models of melanoma, this compound decreases expression of VEGF and suppresses tumor growth. SRPIN340 also prevents pathological retinal neovascularization in vivo.
| Cas No. | 218156-96-8 |
|---|---|
| Purity | ≥98% |
| Formula | C18H18F3N3O |
| Formula Wt. | 349.36 |
| IUPAC Name | N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide |
| Synonym | SRPIN 340 |
| Solubility | DMSO: ≥ 42 mg/mL |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Gammons MV, Lucas R, Dean R, et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014 Jul 29;111(3):477-85. PMID: 25010863.
Gammons MV, Dick AD, Harper SJ, et al. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806. PMID: 23761094.
Karakama Y, Sakamoto N, Itsui Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86. PMID: 20498328.
